Since its founding in 2005, the Global HIV Vaccine Enterprise stakeholders have:
- Increased government, foundation and industry support for HIV vaccine research
- Mobilized more than US$750 million for cutting edge HIV vaccine research
- Promoted new tools, systems and information sharing strategies to speed research
- Supported the creation of collaborative global HIV vaccine development consortia:
- The Collaboration for AIDS Vaccine Discovery (CAVD)
- The Center for HIV-AIDS Immunology (CHAVI)
- Supported efforts to expand HIV vaccine research in developing countries:
- AIDS Vaccine Asian Network (AVAN)
- African AIDS Vaccine Program (AAVP)
- Organized the world’s primary HIV vaccine research conference
- Spearheaded efforts to encourage the best young and early career researchers to enter HIV vaccine research
Moving forward, Enterprise stakeholders are working to accelerate HIV vaccine research progress by:
- Bringing new human and financial resources to the field
- Updating the scientific strategic plan based on the latest research knowledge,
- Keeping global attention focused on the need for an effective HIV vaccine
- Using every scientific and organizational tool available, and develop new ones as needed, to overcome the barriers to developing a safe and effective HIV vaccine.
If your organization is interested in joining the Global HIV Vaccine Enterprise, please contact us at or +1 212-461-3692.
